Purchase this article with an account.
Victoria Gonzalez, Andres Kychenthal, Paola Dorta, Alay Banker, Virgilio Morales-Canton, Maria Ana Martinez-Castellanos; Ocular and Systemic Adverse Events Asociated with Intravitreal Bevacizumab in the Treatment of Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5899.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the ocular and sytemic adverse events associated with intravitreal Bevacizumab for the treatment of Retinopathy of Prematurity
A retrospective study was performed in 262 patients (418 eyes), inyected with intravitreal Bevacizumab. Adverse events were collected and analyzed.
A total of 71 local adverse events were found, including worsening of the retinal detachment, elevation of intraocular pressure, peripheral fibrous avascular membrane, vitreous hemorrage, retinal phlebitis, and cataract. Systemic adverse events included 3 deaths that apparently were not related to intravitreal bevacizumab.
After 7 years of follow up, intravitreal Bevacizumab appears to be safe for treatment for Retinopathy of Prematurity, with treatable ocular adverse events. Systemic abnormalities may be sequelae of prematurity itself and not related to the medication. Longer follow up is needed.
This PDF is available to Subscribers Only